Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes.
Makino
Hirofumi
H
Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-Okayama, Japan. makino@md.okayama-u.ac.jp
Haneda
Masakazu
M
Babazono
Tetsuya
T
Moriya
Tatsumi
T
Ito
Sadayoshi
S
Iwamoto
Yasuhiko
Y
Kawamori
Ryuzo
R
Takeuchi
Masahiro
M
Katayama
Shigehiro
S
D000328:Adult; D000368:Aged; D000419:Albuminuria; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D003928:Diabetic Nephropathies / Q000503:physiopathology* / Q000517:prevention & control*; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D010919:Placebos; D000077333:Telmisartan
D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D010919:Placebos; D000077333:Telmisartan